Themis Medicare Ltd., established in 1969, is a prominent pharmaceutical company involved in the manufacturing of both synthetic bulk drugs and formulations. The company specializes in therapeutic segments including anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, and anaesthetics, with anti-tuberculosis products comprising 60% of its turnover, positioning it as a leading player in this sector. Themis Medicare has expanded its operations through various strategic initiatives, including public equity offerings to finance plant expansions and backward integrations, as well as international collaborations for manufacturing and marketing.
The company has a global presence, highlighted by its subsidiary, Themis Medicare Singapore Pte. Ltd., and joint ventures like Richter Themis Medicare (India) Pvt. Ltd. and Carpo Medical Limited in the UK. Additionally, Themis has launched innovative products such as 'Themiseal' across multiple international markets. Despite changes, such as the cessation of its Hungarian subsidiary, the company continues to grow its portfolio and international reach, catering to both human and veterinary pharmaceutical needs.
